文献速递基础与转化研究临床试验与 GCP医学人工智能与信息学

利妥昔单抗与托珠单抗治疗类风湿关节炎:基于滑膜活检生物标志物的4期R4RA随机试验分析

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
PubMed 文献 · Nat Med · 2022-05-19

R4RA随机试验(n=164)对类风湿关节炎患者滑膜活检进行组织学/分子分析,发现低/无B细胞分子特征者对利妥昔单抗应答低于托珠单抗;鉴定出与两种药物应答相关的体液免疫基因特征及难治患者的基质/成纤维细胞特征;机器学习算法预测利妥昔单抗应答AUC=0.74、托珠单抗AUC=0.68、多药耐药AUC=0.69。

要点

  • 滑膜低/无B细胞分子特征患者对利妥昔单抗应答低于托珠单抗。
  • 体液免疫基因特征与利妥昔单抗和托珠单抗应答相关,基质/成纤维细胞特征见于全药物难治患者。
  • 机器学习算法预测利妥昔单抗应答AUC=0.74、托珠单抗AUC=0.68、多药耐药AUC=0.69。

核心结论

  • 疾病内型由病变组织不同分子病理通路驱动,决定不同临床和治疗应答表型。
  • 将分子病理特征整合入临床算法有助于优化现有药物使用并指导难治患者新药研发。

研究设计与样本

  • 4期R4RA随机临床试验的滑膜活检组织学/分子分析,样本量n=164。

主要发现

  • 滑膜B细胞分子特征低/无的患者对利妥昔单抗应答低于托珠单抗。
  • 鉴定出与利妥昔单抗和托珠单抗应答相关的体液免疫应答基因特征,以及全药物难治患者的基质/成纤维细胞特征。
  • 治疗后滑膜基因表达和细胞浸润变化显示利妥昔单抗与托珠单抗在应答/无应答机制上的差异。
  • 采用十乘十倍嵌套交叉验证开发机器学习算法预测利妥昔单抗应答AUC=0.74、托珠单抗应答AUC=0.68、多药耐药AUC=0.69。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 应答/无应答的确切机制仍有待确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5-20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment-response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Rivellese F, Surace AEA, Goldmann K, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022. PMID: 35589854. doi:10.1038/s41591-022-01789-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。